
Alembic Pharma Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- US business:
- - Expected to grow with broader product portfolio and new product launches (10-15 launches planned in FY25).
- - Volume increase observed in existing products; new facilities ramp-up to improve operating leverage and margins.
- - Price erosion continues but is less severe than before; depends on product and competition.
- - Focus on complex products like injectables, peptides, oncology, which may reduce price erosion and offer larger opportunities.
- Ex-US markets (Europe, Canada, Australia, Brazil, South Africa):
- - Steady growth expected at ~15% CAGR, driven through partners.
- API business:
- - Continues to be a good margin business with steady growth (~11-15% CAGR).
- - Some near-term lumpiness expected, followed by return to regular growth.
- Domestic India business:
- - 9% growth reported despite muted demand in some segments.
- - Specialty therapies and Animal Health showing strong growth.
- Overall:
- - Incremental operating leverage expected as new facilities grow utilization.
- - No major CAPEX planned except maintenance and API expansions.
See what Alembic Pharma management said on margin guidance — free account, 30 seconds.
Fundraise plans
- Alembic Pharmaceuticals Limited did not mention any current or future new fundraising through debt or equity during the call.
- The company highlighted that their gross borrowings have reduced from Rs. 686 crores in December 2022 to Rs. 575 crores in December 2023.
- They reported having Rs. 156 crores of cash on hand as of December 2023.
- No large CAPEX is planned for the international business other than maintenance CAPEX and some API expansions.
- The company repaid borrowings and paid dividends from net cash inflows.
- Overall, the company appears focused on optimizing existing resources and ramping up new facilities without raising additional capital through debt or equity at this time.
See what Alembic Pharma management said on order book — free account, 30 seconds.
Capex plans
Yes- No large CAPEX needed for the international business currently; only maintenance CAPEX and some API expansion planned.
- API expansion includes growth in therapies such as GLP-1 and debottlenecking.
- Focus on investments in new capabilities like injectables, peptides, and oncology.
- The shift toward more complex products aims to reduce price erosion and provide bigger product opportunities, especially in the US market.
- New facilities are operational but currently have low capacity utilization; operating leverage is expected to improve as product volumes increase.
- Some targeted CMO (Contract Manufacturing Organization) opportunities are being pursued to improve plant utilization.
- No specific timelines or large-scale new capital investments mentioned beyond these incremental expansions and optimizations.
Track Alembic Pharma — get its next earnings analysis in your feed
How does Alembic Pharma rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Alembic Pharma rank in Pharmaceuticals & Biotechnology?
Compare Alembic Pharma against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Alembic Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem